Pharmaceutical processing plays a pivotal role in determining the therapeutic success of antiviral formulations, particularly in the management of hepatitis virus infections. Beyond the discovery of potent antiviral compounds, the formulation strategy and particle processes directly influence drug release behavior, bioavailability, and ultimately, clinical efficacy. In this study, a mathematical model is developed to explore the dynamic interaction between viral load, drug concentration, and immune response, while incorporating the influence of pharmaceutical processing parameters on the drug release profile. The model captures how drug formulation—including particle size, granulation, and controlled-release systems—shapes the release kinetics and enhances antiviral action. By simulating various release scenarios through a pharmaceutical processing-dependent function, this study offers valuable perspective into optimizing antiviral formulations for improved therapeutic outcomes.

Despite advances in drug discovery, the integration of pharmaceutical processing characteristics into predictive viral dynamic models remains underexplored. This research addresses this gap by bridging pharmaceutical engineering and biological modeling, offering a systematic framework to guide the design of more effective and patient-centric antiviral therapies. Furthermore, this approach enables quantitative evaluation of how formulation changes impact viral suppression over time, providing a critical perspective for optimizing treatment schedules. This holistic strategy could significantly enhance personalized medicine in antiviral treatment planning.